10-Q: Bausch Health Reports Second Quarter 2024 Results, Revenue Up 11%

Bausch Health Companies Inc. reports an 11% increase in revenue for the second quarter of 2024, driven by growth across all segments.

Summary

• Bausch Health Companies Inc. reported a revenue increase of 11% for the second quarter of 2024, reaching $2.403 billion, compared to $2.167 billion in the same period last year.
• The revenue growth was attributed to incremental sales from acquisitions, higher volumes, and improved net pricing, partially offset by unfavorable foreign currency impacts and divestitures.
• Operating income decreased to $389 million from $412 million year-over-year, due to increased selling, general, and administrative expenses and other expenses, partially offset by a decrease in asset impairments.
• Net income attributable to Bausch Health was $10 million, compared to $26 million in the second quarter of 2023.
• For the first six months of 2024, revenue increased by 11% to $4.556 billion, compared to $4.111 billion in the same period last year.
• The company reported a net loss attributable to Bausch Health of $54 million for the first six months of 2024, compared to a net loss of $175 million for the same period in 2023.
• The company's weighted average stated interest rate for outstanding debt obligations was 8.00% as of June 30, 2024.

Sentiment

Score: 5

Explanation: The document presents mixed results with revenue growth offset by decreased profitability and increased expenses. The company faces significant risks and challenges, including debt obligations and legal proceedings. The sentiment is neutral to slightly negative.

Positives

• Revenue growth was driven by strong performance across all segments.
• The company saw a decrease in asset impairments compared to the same period last year.
• The company reported a net loss attributable to Bausch Health of $54 million for the first six months of 2024, compared to a net loss of $175 million for the same period in 2023, indicating an improvement in financial performance.
• The company repurchased and retired a portion of its senior unsecured notes, resulting in a gain on extinguishment of debt.

Negatives

• Operating income decreased year-over-year due to increased selling, general, and administrative expenses.
• Net income attributable to Bausch Health decreased in the second quarter of 2024 compared to the same period in 2023.
• The company's interest expense increased due to new debt obligations.

Risks

• The company faces risks related to the ongoing Russia-Ukraine war and the Israel-Hamas conflict, which could impact its operations and financial results.
• The company is subject to potential impacts from the implementation of the OECD's Inclusive Framework on global minimum corporate tax rates.
• The company faces risks related to health care reform and potential pricing pressures on its products.
• The company faces risks related to generic competition and loss of exclusivity for certain of its products.
• The company is involved in various legal proceedings, including product liability, intellectual property, and antitrust litigation, which could have a material adverse effect on its business.
• The company's ability to satisfy its debt obligations depends on its future operating performance and ability to improve its capital structure.

Future Outlook

The company continues to evaluate all relevant factors and considerations related to completing the B+L Separation, including the Xifaxan Generics Litigation. The company expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over the next twelve months. The company continues to take steps to ensure compliance with its financial maintenance covenant and may take other actions to reduce its debt levels and improve its capital structure to align with the Companys long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.

Management Comments

• The company continues to execute on a multi-year plan designed to transform and bring out value in our Company, which includes focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management.
• We believe that these and other actions we have taken have helped to focus our operations and improve our capital structure.
• We believe that these measures, along with our continued commitment to improving peoples lives through our health products, help position us to unlock potential value across our portfolio of assets by separating our eye health and pharmaceutical businesses.

Industry Context

The company operates in the pharmaceutical and medical device industries, which are subject to intense competition, regulatory scrutiny, and pricing pressures. The company's performance is influenced by factors such as generic competition, patent expirations, and healthcare reforms. The company's strategic focus on core businesses and capital structure management reflects broader industry trends towards specialization and financial discipline.

Comparison to Industry Standards

• Bausch Health's revenue growth of 11% in the second quarter of 2024 is a positive sign, but it is important to compare this to the performance of its peers in the pharmaceutical and medical device industries.
• Companies like Johnson & Johnson, AbbVie, and Medtronic, which are major players in the healthcare sector, have reported varying results in recent quarters, with some experiencing growth and others facing challenges.
• Bausch Health's operating income decreased year-over-year, which is a concern, and it is important to compare this to the operating margins of its competitors to assess its relative profitability.
• The company's net income attributable to Bausch Health was $10 million, compared to $26 million in the second quarter of 2023, which is a decline, and it is important to compare this to the net income of its peers to assess its relative performance.
• The company's weighted average stated interest rate of 8.00% as of June 30, 2024, is relatively high, and it is important to compare this to the interest rates of its competitors to assess its financial risk.
• The company's strategic focus on core businesses and capital structure management is consistent with industry trends, but its ability to execute these strategies effectively will determine its long-term success.

Legal Proceedings

• The company is involved in various legal proceedings, including product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues.
• The company is a defendant in multidistrict antitrust litigation related to generic pharmaceutical pricing.
• The company is involved in ongoing patent litigation related to Xifaxan, Trulance, Lumify and PreserVision products.
• The company is involved in product liability lawsuits related to Shower to Shower body powder.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the potential for future capital raises.
• Employees may be impacted by changes in compensation and benefits plans, as well as potential restructuring activities.
• Customers may be impacted by changes in product pricing and availability.
• Creditors may be impacted by the company's ability to service its debt obligations.

Next Steps

• The company will continue to evaluate all relevant factors and considerations related to completing the B+L Separation.
• The company will continue to monitor its capital structure and evaluate opportunities to simplify its business and improve its capital structure.
• The company will continue to monitor the market conditions and trends in business performance for all its reporting units.
• The company will continue to take steps to ensure compliance with its financial maintenance covenant and may take other actions to reduce its debt levels and improve its capital structure.

Key Dates

Keywords

Bausch Health, revenue, operating income, net income, debt, pharmaceuticals, medical devices, gastroenterology, neurology, dermatology, eye health, Bausch + Lomb, XIIDRA, generic competition, legal proceedings